Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels. Some changes of inflammatory mediators were also observed, including hsCRP, which may suggest an anti-inflammatory effect.
Lupo M.G., Arcidiacono D., Zaramella A., Fimiani F., Calabro P., Cefalu AB, et al. (2021). Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile. ATHEROSCLEROSIS PLUS, 43, 7-9 [10.1016/j.athplu.2021.05.001].
Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile
Cefalu ABInvestigation
;Averna MMembro del Collaboration Group
;
2021-06-19
Abstract
Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels. Some changes of inflammatory mediators were also observed, including hsCRP, which may suggest an anti-inflammatory effect.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients.pdf
accesso aperto
Tipologia:
Versione Editoriale
Dimensione
378.74 kB
Formato
Adobe PDF
|
378.74 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
